BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.

Breast Cancer Res · 2023 · PMC10280902 · PMID 37337299

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Therefore, associations were analyzed by inverse probability weight corrected Cox regression, which showed a trend toward greater pertuzumab benefit in the patients with HER2-type tumors, similar to our findings.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.